Aclaris Therapeutics Receives Fast Track Designation for Modzatinib (ATI-2138) for Moderate to Severe Lichen Planus (LP)

RegulatoryModzatinibPositive

AI Analysis

Summary

Aclaris Therapeutics announced that modzatinib (ATI-2138) has received Fast Track Designation from the FDA for the treatment of moderate to severe lichen planus. The designation is intended to expedite development and review of drugs addressing serious or life-threatening conditions with unmet medical needs.

Outcome Details

Fast Track Designation granted

Importance:6/10

Sentiment:

0.70

Fast Track DesignationFDALichen PlanusImmuno-inflammatoryClinical Stage

Related Companies

$ACRS

Read the original article

Published by Drugs.com Clinical Trial Results on August 6, 2026 11:08 PM

Read Original